July 21st, 2015 - Axxam SpA (Milan/Italy), a leading provider of discovery services has entered into a multi-year collaboration agreement with Bayer HealthCare (Bayer), a global pharmaceutical company. The aim of this collaboration is to provide high level services to support Bayer’s strong commitment to discover new therapies for diseases with high unmet medical need.
Axxam SpA enters into a collaboration agreement with Bayer HealthCare for the provision of Drug Discovery Services
Axxam enters into a research collaboration with The University of Texas MD Anderson Cancer Center for Assay Development and High Throughput Screening of selected targets in oncology
June 18th, 2015 – Axxam SpA (Milan/Italy), a leading provider of discovery services, has entered into a multi-year collaboration with the Institute for Applied Cancer Science (IACS) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify lead chemical matters against novel oncology targets provided by MD Anderson. The collaboration leverages Axxam’s expertise in assay development, Axxam’s fully automated screening platforms and access to Axxam’s novel compound collection AxxDiv2.0. The collaboration builds on a strong working relationship between Axxam and MD Anderson.
Axxam announces the appointment of Dr. Russell Thomas as Director of Discovery Research
May 4th, 2015 – Axxam SpA (Milan/Italy), a privately owned contract research and discovery company, announced today that Dr. Russell Thomas has joined the company as Director of Discovery Research. Russell brings to Axxam considerable industry experience that spans from target discovery to clinical proof of concept at Siena Biotech, Proteros, Evotec and GlaxoWellcome.
Russell is joining Axxam from Siena Biotech, where he was initially head of Medicinal Chemistry, before becoming Director of Project Operations and External Alliances and more recently General Manager. In these various roles Russell guided a range of neuroscience and oncology projects from initial hit validation and subsequent optimization, leading to a number of preclinical and clinical candidates. He is one of the inventors of selisistat, which is currently progressing through clinical trials as a potential disease modifying approach to Huntington’s disease.
During his time at Proteros, in the role of Vice President of Lead Discovery, Russell had strategic responsibility for all existing and potential new collaborations with pharmaceutical and biotech partners and played a key role in the start-up of Rodin Therapeutics with Atlas Venture.
At Evotec, as a Department Head in Medicinal Chemistry, Russell was responsible for guiding a range of discovery alliances with international pharmaceutical and biotech companies. These alliances led to the delivery of a number of preclinical and clinical candidates.
In the seven years that Russell spent at Glaxo, subseqently GlaxoWellcome, he worked as a senior medicinal chemist, mainly in the field of antibacterials. Originally from Swansea in Wales, he obtained a Ph.D in synthetic organic chemistry in the group of Prof. Stan Roberts at Exeter University, after graduating in Chemistry from the University of Kent.
Aptuit LLC and Axxam SpA announce Strategic Alliance for Integrated Drug Discovery Services.
Commence major integrated discovery program for large Pharma sponsor
Greenwich, CT and Milan (Italy) - April 14, 2015 – Aptuit LLC, a premier global drug discovery and development CRO and Axxam SpA, a leading discovery company with expertise in target biology and a broad range of early phase discovery solutions, announced a strategic alliance to provide comprehensive and integrated services from gene to high quality candidates and beyond. This partnership will allow the companies to offer the best-in-class fully integrated drug discovery and development services, supported by a culture of scientific excellence and innovation.
Aptuit and Axxam are also delighted to announce that the partnership has already resulted in the commencement of the first significant joint integrated project with a large pharma sponsor.